Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Nov 28, 2023
Date Accepted: Feb 1, 2024

The final, peer-reviewed published version of this preprint can be found here:

Benefits, Harms, and Stakeholder Perspectives Regarding Opioid Therapy for Pain in Individuals With Metastatic Cancer: Protocol for a Descriptive Cohort Study

Jones K, White G, Bennett A, Bulls H, Escott P, Orris S, Escott E, Fischer S, Hamm M, Krishnamurti T, Wong R, LeBlanc T, Liebschutz J, Meghani S, Smith C, Temel J, Ritchie C, Merlin J

Benefits, Harms, and Stakeholder Perspectives Regarding Opioid Therapy for Pain in Individuals With Metastatic Cancer: Protocol for a Descriptive Cohort Study

JMIR Res Protoc 2024;13:e54953

DOI: 10.2196/54953

PMID: 38478905

PMCID: 10973954

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Opioid therapy for pain in individuals with metastatic cancer: benefits, harms, and stakeholder perspectives: A Protocol Paper

  • Katie Jones; 
  • Gretchen White; 
  • Antonia Bennett; 
  • Hailey Bulls; 
  • Paula Escott; 
  • Sarah Orris; 
  • Elizabeth Escott; 
  • Stacey Fischer; 
  • Megan Hamm; 
  • Tamar Krishnamurti; 
  • Risa Wong; 
  • Thomas LeBlanc; 
  • Jane Liebschutz; 
  • Salimah Meghani; 
  • Cardinale Smith; 
  • Jennifer Temel; 
  • Christine Ritchie; 
  • Jessica Merlin

ABSTRACT

Background:

Opioids are a key component of pain management among patients with metastatic cancer pain. However, the evidence base available to guide opioid-related decision-making in individuals with advanced cancer is limited.

Objective:

This manuscript outlines the protocol the “Opioid therapy for pain in individuals with metastatic cancer: The BEnefits, harms, and STakeholder perspectives (BEST) study”.

Methods:

This is a multicenter, prospective cohort study that aims to enroll 630 patients with advanced cancer, 20 care partners, and 20 clinicians (670 total participants).

Results:

The data collection is underway at four clinical sites and results will be reported in future manuscripts.

Conclusions:

Upon successful execution of our study protocol, we anticipate the development of a comprehensive evidence-base on opioid therapy in individuals with advanced cancer guided by the Behavioral Decision Research framework. Clinical Trial: N/a


 Citation

Please cite as:

Jones K, White G, Bennett A, Bulls H, Escott P, Orris S, Escott E, Fischer S, Hamm M, Krishnamurti T, Wong R, LeBlanc T, Liebschutz J, Meghani S, Smith C, Temel J, Ritchie C, Merlin J

Benefits, Harms, and Stakeholder Perspectives Regarding Opioid Therapy for Pain in Individuals With Metastatic Cancer: Protocol for a Descriptive Cohort Study

JMIR Res Protoc 2024;13:e54953

DOI: 10.2196/54953

PMID: 38478905

PMCID: 10973954

The author of this paper has made a PDF available, but requires the user to login, or create an account.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.